Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04541212 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia

Study acronym: CarChem
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 19 words
    • Site details revised at 4 of 6 sites
  2. Primary completion date: Apr 30, 2025 to Apr 30, 2027v16 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 225 to confirmed 169
    • Study completion date: Apr 30, 2027 to Sep 30, 2027
    • Site details revised at 6 of 6 sites
  3. Enrollment target: 300 to 225v15
  4. Study sites: 5 to 6
    • Primary completion date: Jan 2026 to Apr 30, 2025
    • Study completion date: Jan 2026 to Apr 30, 2027
    v14
  5. Study sites: 3 to 5v13
Show 11 earlier versionsHide 11 earlier versions
  1. Eligibility criteria shortened, about 6 wordsv12
  2. Primary and study completion dates: Jan 2025 to Jan 2026
    • Study sites: 2 to 3
    v11
  3. Primary completion date: Jan 2024 to Jan 2025
    • Study completion date: Mar 2024 to Jan 2025
    v10
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Nov 15, 2021 to Dec 2, 2021
    v9
  5. Start date: Sep 30, 2021 to Nov 15, 2021v8
  6. Start date: Jun 2021 to Sep 30, 2021v7
  7. Primary completion date: Dec 2023 to Jan 2024
    • Study completion date: Dec 2023 to Mar 2024
    • Start date: May 2021 to Jun 2021
    v6
  8. Start date: Mar 2021 to May 2021v5
  9. Start date: Feb 2021 to Mar 2021v4
  10. Start date: Dec 2020 to Feb 2021v3
  11. Start date: Sep 2020 to Dec 2020
    • Primary and study completion dates: Sep 2023 to Dec 2023
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Montreal Heart Institute
25 trials monitored
See 4 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
This is an observational study of the occurrence of cardiac toxicity in patients with breast cancer,lymphoma or leukemia receiving chemotherapy including an anthracycline. Patients will be identified at the oncology clinic and will be included in the study if all eligible criteria are met. The study will involve retrospective and prospective evaluations. Safety will be assessed through reporting of serious adverse events (SAEs) related to study procedures.
Trial Details
NCT Number NCT04541212
Lead Sponsor Montreal Heart Institute
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Breast Cancer, Lymphoma, Leukemia
Related terms Breast Neoplasms, Leukemia, Lymphoma
Enrollment 169 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov